3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
8
Uveal Melanoma
1
Stomach Neoplasms
1
Resectable Hepatocellular Carcinoma
1
Neoplasms
1
Liver Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Pancreatic Cancer
1
Interventions
Magnetic Resonance Spectroscopy
11
Specimen Handling
8
X-Rays
7
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Biopsy
6
olaparib
4
ulixertinib
3
trametinib
3
palbociclib
3
larotrectinib
3
ivosidenib
3
erdafitinib
3
dabrafenib
3
Vemurafenib
3
tipifarnib
2
tazemetostat
2
selpercatinib
2
ensartinib
2
durvalumab
2
Nivolumab
2
LY3023414
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Cisplatin
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
sonidegib
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
ADI PEG20
×
Gastrointestinal
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled